Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  Rosa & Co. LLC, a ... and simulation research, today announced it has two posters ... for Clinical Pharmacology and Therapeutics meeting in ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... a poster describing a quantitative systems pharmacology approach for ...
(Date:3/3/2015)... Mass. (PRWEB) March 03, 2015 Cambridge ... by Semantic Web technology, today announced that it has ... Companies That Matter in Knowledge Management.’ , To ... group of colleagues, analysts and system integrators who identify ... delivery of the right information to the right people ...
(Date:3/3/2015)... March 3, 2015 Elsevier,s ... for implementing competency-based training to comply with new CMS ... is offering a new crosswalk tool to ... competency-based training for direct service workers as a means ... Services (CMS) regulations. CMS amended the regulations, ...
(Date:3/3/2015)... GlobalStemCellsGroup.com has recruited Mario Camacho Alcocer ... researcher and founding partner of Criogenix SA de CV ... professors who will teach the “Diplomat in Cell Therapy ... is a private company registered in the National Record ... (RENIECYT). , Camacho Alcocer will teach two-day, interactive training ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... developed a novel mouse model mimicking human preterm labor have ... it to stop the problem.   (Logo: ... online the week of Oct. 24 by PNAS ... researchers report their findings may lead to new strategies for ...
... Inc. ("DLVR") - a privately-held biotechnology company currently ... proprietary high density lipoprotein-like nanoparticle -announced today that ... bringing the total raised to $2 million in ... University Health Network (UHN) and the Ontario Institute ...
... 24, 2011 Ventana Medical Systems, Inc. (Ventana), a ... the U.S. Food and Drug Administration (FDA) for the ... with associated VIRTUOSO software and iScan Coreo Au scanner. ... workflow solution for determining HER2 (4B5) expression in breast ...
Cached Biology Technology:Study Hints at Possible Therapeutic Strategy to Combat Premature Birth 2Study Hints at Possible Therapeutic Strategy to Combat Premature Birth 3DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 2DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 3Ventana Receives FDA Clearance for HER2 (4B5) Image Analysis and Digital Read Applications 2
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... N.J. - The inaugural Global Conference on Systems ... in Washington, DC, focuses on the convergence of complex ... The goal of the ... around targeted complex systems, examined by domain, each successive ...
... to rise scientists are presented with the complex challenge ... paper published in Insect Conservation and Diversity , ... challenge. Twentieth-Century global warming of approximately 0.6˚C has ... challenge facing ecologists and evolutionary biologists is to predict ...
... A major obstacle to HIV research is the virus,s ... traditional tools, like the humble lab mouse, can deliver only ... Central,s open access Journal of Biology have made ... that has key features of HIV infection without being infected ...
Cached Biology News:First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2How can scientists measure evolutionary responses to climate change? 2A reductionist approach to HIV research 2
... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
... SR-101 Labeled Substrates (red fluorescence; Ex=590 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
Biology Products: